SLG
CSTL icon

Stanley-Laman Group’s Castle Biosciences CSTL Stock Holding History

Stanley-Laman Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-43,875
Closed -$963K – 246
2022
Q2 		$963K Buy
43,875
+3,659
+9% +$85K 0.17% 167
2022
Q1 		$1.8M Buy
40,216
+242
+0.6% +$10K 0.25% 139
2021
Q4 		$1.71M Buy
+39,974
New +$2.09M 0.2% 151

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Stanley-Laman Group's CSTL Position: Q3 2022 in Review

Stanley-Laman Group sold out of Castle Biosciences (CSTL) in Q3 2022, closing a stake of 43,875 shares — an estimated $963K sold.

Stanley-Laman Group first reported a position in CSTL in Q4 2021 and held it in 3 quarters. The position peaked at $1.8M in Q1 2022. 157 funds tracked by Wall St. Rank hold CSTL as of Q3 2022.

  • Stanley-Laman Group reported no remaining Castle Biosciences position as of Q3 2022 after selling out during the quarter.
  • Stanley-Laman Group sold 43,875 Castle Biosciences shares in Q3 2022, an estimated $963K.
  • Stanley-Laman Group first reported a position in Castle Biosciences in Q4 2021 and held it in 3 quarters.
  • Stanley-Laman Group's Castle Biosciences position peaked at $1.8M in Q1 2022.
  • 157 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2022.

Based on Stanley-Laman Group's 13F filing for Q3 2022, filed 18 Oct 2022.